Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733518 | 0.89 | KDM4E (0.39) | PDK2TGFBR1KMOKDM4CKDM4E | |
| SCHEMBL480633 | 0.89 | SLC6A3 (0.42) | SLC6A3SLC6A4BDKRB1PDK2SLC6A2 | |
| SCHEMBL480017 | 0.89 | KDM4E (0.39) | PDK2TGFBR1KMOKDM4CKDM4E | |
| SCHEMBL754770 | 0.86 | KMO (0.43) | PDK2KMOKDM4C | |
| SCHEMBL479917 | 0.86 | KMO (0.43) | PDK2KMOKDM4C | |
| SCHEMBL837203 | 0.84 | CHEK1 (0.39) | KMOKDM4CKDM4E | |
| SCHEMBL480056 | 0.83 | BDKRB1 (0.42) | BDKRB1KMOPTGER4 | |
| SCHEMBL15789725 | 0.81 | KMO (0.38) | KMOKDM4C | |
| SCHEMBL480055 | 0.81 | PDK2 (0.35) | BDKRB1PDK2TGFBR1KMOKDM4C | |
| SCHEMBL837915 | 0.79 | MRGPRX4 (0.41) | KMOKDM4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | SLC6A3 1157/4885SLC6A4 525/4885BDKRB1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.